Progression-free survival by local investigator versus independent central review: comparative analysis of the AGO-OVAR16 Trial.

Abstract

BACKGROUND Analysis of progression-free survival (PFS) as the primary endpoint in advanced epithelial ovarian, fallopian tube, and primary peritoneal cancer (AEOC) trials may be confounded by the difficulty of radiologic evaluation of disease progression and the potential for discrepancy between investigator and blinded independent central assessments. PFS… (More)
DOI: 10.1016/j.ygyno.2014.11.074

Topics

  • Presentations referencing similar topics